1. Search Result
Search Result
Results for "

positive inotropic properties

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-129733

    Na+/K+ ATPase Cardiovascular Disease
    LND 623 is an inotropic aminosteroid with positive inotropic properties. LND 623 inhibits Na +/K + ATPase activity. The LD50 of LND 623 infused i.v. is around 45 mg/kg, a value ten times higher than the LD50 for Ouabain (HY-B1457) .
    LND 623
  • HY-101811

    Phosphodiesterase (PDE) Cardiovascular Disease
    LAS-31180 is an inhibitor of phosphodiesterase 3, with positive inotropic and vasodilator properties.
    LAS-31180
  • HY-113847

    UK-61260-27

    Phosphodiesterase (PDE) Cardiovascular Disease
    Nanterinone mesylate (UK-61260-27) is an orally active and positive inotropic and balanced-type vasodilating agent, partially based on phosphodiesterase III inhibition with venodilating properties. Nanterinone mesylate is promising for research of cardiovascular diseases .
    Nanterinone mesylate
  • HY-116119

    Sodium Channel Cardiovascular Disease
    BDF 9148 is a sodium-channel activator with antiarrhythmic properties that produces a significant CAMP-independent positive inotropic effect in left ventricular myocardium from failing hearts. BDF 9148 is promising for research of myocardial failure .
    BDF 9148
  • HY-105931

    RS-82856

    Phosphodiesterase (PDE) Cardiovascular Disease Endocrinology
    Lixazinone (RS-82856) is a selective inhibitor of cGMP-inhibited phosphodiesterase (PDE3) with an IC50 value of 22 nM. Lixazinone exhibits positive inotropic effects, afterload reduction and antithrombotic properties. Lixazinone increases cyclic adenosine monophosphate (cAMP) levels in human platelets, inhibits thrombin-induced aggregation of human platelets, and blocks the photolabeling of PDE3 active sites by [ 32P]cGMP. Lixazinone can be used in the research of polycystic kidney disease and congestive heart failure .
    Lixazinone
  • HY-113822

    RS-82856 hydrogensulfate

    Phosphodiesterase (PDE) Cardiovascular Disease Endocrinology
    Lixazinone (RS-82856) hydrogensulfate is a selective inhibitor of cGMP-inhibited phosphodiesterase (PDE3) with an IC50 value of 22 nM. Lixazinone hydrogensulfate exhibits positive inotropic effects, afterload reduction and antithrombotic properties. Lixazinone hydrogensulfate increases cyclic adenosine monophosphate (cAMP) levels in human platelets, inhibits thrombin-induced aggregation of human platelets, and blocks the photolabeling of PDE3 active sites by [ 32P]cGMP. Lixazinone hydrogensulfate can be used in the research of polycystic kidney disease and congestive heart failure .
    Lixazinone hydrogensulfate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: